Metabolic syndrome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a post hoc analyses of the EMPA-REG OUTCOME trial

BACKGROUND: Patients with type 2 diabetes (T2D) and metabolic syndrome (MetS) are at greater cardiovascular risk than those with T2D without MetS. In the current report we aim to study the characteristics, cardio-renal outcomes and the effect of empagliflozin in patients with MetS enrolled in the EM...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Cardiovasc Diabetol
Prif Awduron: Ferreira, João Pedro, Verma, Subodh, Fitchett, David, Ofstad, Anne Pernille, Lauer, Sabine, Zwiener, Isabella, George, Jyothis, Wanner, Christoph, Zinman, Bernard, Inzucchi, Silvio E.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: BioMed Central 2020
Pynciau:
Original Investigation
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7694291/
https://ncbi.nlm.nih.gov/pubmed/33243221
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-020-01174-6
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg